De Novo Steatosis Post-Liver Transplantation: Prevalence and Risk Factors
Non-hepatic metabolic conditions represent crucial drivers of post-liver transplant morbidity and mortality.
Commented Articles
PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.
Read MoreDe Novo Steatosis Post-Liver Transplantation: Prevalence and Risk Factors
Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), affects 30% of adults worldwide and up to 40% of those with type 1 diabetes mellitus (T1DM)
Research Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient Care
Both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), NAFLD’s inflammatory and progressive subtype, are the histologic manifestations of a heterogeneous disease intricately linked with metabolic disorders.
The Long Road to NASH Therapeutics: Uncovering Valuable Insights
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are affected by non-alcoholic fatty liver disease (NAFLD).
Liver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?
Liver-related events contribute to a small proportion of mortality within the collective cohort of patients with non-alcoholic fatty liver disease (NAFLD).
NAFLD and Pancreatic Steatosis: A Bidirectional Relationship?
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
NAFLD and Cardiovascular Diseases: What is The Link?
Recent research into non-alcoholic fatty liver disease (NAFLD) has noted its distinct association with cardiovascular diseases (CVDs).
Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Insights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver disease (NAFLD), accounts for a significant proportion of this burden.
NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.